Equities

MiMedx Group Inc

MDXG:NAQ

MiMedx Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.23
  • Today's Change0.05 / 0.81%
  • Shares traded452.79k
  • 1 Year change-20.64%
  • Beta1.9863
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for MiMedx Group Inc have a median target of 12.00, with a high estimate of 14.00 and a low estimate of 11.00. The median estimate represents a 92.62% increase from the last price of 6.23.
High124.7%14.00
Med92.6%12.00
Low76.6%11.00

Earnings history & estimates in USD

On Jul 31, 2024, MiMedx Group Inc reported 2nd quarter 2024 earnings of 0.12 per share. This result exceeded the 0.08 consensus of the 7 analysts covering the company and outperformed last year's 2nd quarter results by 0.12.
The next earnings announcement is expected on Oct 28, 2024.
Average growth rate+150.69%
MiMedx Group Inc reported annual 2023 earnings of 0.37 per share on Feb 28, 2024.
Average growth rate-19.74%
More ▼

Revenue history & estimates in USD

MiMedx Group, Inc. had 2nd quarter 2024 revenues of 87.21m. This missed the 88.92m consensus estimate of the 7 analysts following the company. This was 21.67% above the prior year's 2nd quarter results.
Average growth rate+1.83%
MiMedx Group, Inc. had revenues for the full year 2023 of 321.48m. This was 20.03% above the prior year's results.
Average growth rate+1.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.